SCHEMBL1496588

SCHEMBL1496588

OCC(O)COc1ccc(Br)cc1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.58
MAPK1 P28482 4/20 0.55
KDM4E B2RXH2 3/20 0.55
TDP1 Q9NUW8 2/20 0.55
KMT2A Q03164 4/20 0.54
ALDH1A1 P00352 4/20 0.54
MEN1 O00255 3/20 0.54
HPGD P15428 2/20 0.54
GAA P10253 1/20 0.54
HTT P42858 1/20 0.54
AR P10275 1/20 0.53
TSHR P16473 2/20 0.53
USP2 O75604 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.50
POLB P06746 2/20 0.46
LMNA P02545 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18991198 1.00 MAPT (0.58) MAPTMAPK1KDM4ETDP1KMT2A
SCHEMBL12663858 1.00 MAPT (0.58) MAPTMAPK1KDM4ETDP1KMT2A
SCHEMBL6228324 0.89 AR (0.61) MAPTMAPK1KDM4EKMT2AALDH1A1
SCHEMBL1496796 0.84 MAPK1 (0.59) MAPTMAPK1KDM4ETDP1KMT2A
SCHEMBL11465309 0.84 NPSR1 (0.63) MAPTMAPK1KDM4EKMT2AALDH1A1
SCHEMBL8811629 0.83 AR (0.56) MAPTMAPK1KDM4EKMT2AALDH1A1
SCHEMBL5010945 0.83 AR (0.56) MAPTMAPK1KDM4EKMT2AALDH1A1
SCHEMBL24933316 0.83 MAPT (0.50) MAPTMAPK1KDM4ETDP1KMT2A
SCHEMBL1496558 0.82 MAPT (0.57) MAPTMAPK1KDM4ETDP1KMT2A
SCHEMBL1496758 0.82 MAPK1 (0.62) MAPTMAPK1KDM4ETDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360082-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2024-10-31 US disclosed
EP-3978472-B1 BIARYL MONABACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME LLC (US) 2024-10-16 EP disclosed
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP disclosed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN disclosed
CN-111171014-B Monocyclolactam compounds and uses thereof 南京圣和药业股份有限公司 2023-11-07 CN disclosed
US-11795169-B2 MAP4K4 inhibitors IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-10-24 US disclosed
US-11795169-B2 MAP4K4 inhibitors IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-10-24 US disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed
CN-112771040-B Monocyclic lactam compounds and uses thereof 南京圣和药业股份有限公司 2022-10-18 CN disclosed
EP-1828127-A2 INSECTICIDAL BIS(SUBSTITUTED PHENYL)-1-äÝ4-(SATURATED HETEROCYCLYL-SUBSTITUTED)PHENYLMETHYL¨-(4-PIPERIDYL)üMETHANE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2007-09-05 EP disclosed
WO-2006065659-A2 INSECTICIDAL BIS(SUBSTITUTED PHENYL)-1-{[4-(SATURATED HETEROCYCLYL-SUBSTITUTED)PHENYLMETHYL]-(4-PIPERIDYL)}METHANE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2006-06-22 WO disclosed
US-6995110-B2 Complex catalyst, process for producing the complex catalyst, and process for producing alcohol derivative with the complex catalyst SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-02-07 US disclosed
US-20040077487-A1 Complex catalyst, process for producing the complex catalyst, and process for producing alchohol derivative with the complex catalyst SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-04-22 US disclosed
EP-1380342-A1 COMPLEX CATALYST, PROCESS FOR PRODUCING THE COMPLEX CATALYST, AND PROCESS FOR PRODUCING ALCOHOL DERIVATIVE WITH THE COMPLEX CATALYST SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2004-01-14 EP disclosed
US-4209447-A FUNGICIDES, BACTERICIDES JANSSEN PHARMACEUTICA N.V. (BE) 1980-06-24 US disclosed
US-4139540-A FUNGICIDE, BACTERICIDE INTERMEDIATE JANSSEN PHARMACEUTICA N.V. (BE) 1979-02-13 US disclosed
US-4119641-A ANTIFUNGAL, ANTIBACTERIAL AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 1978-10-10 US disclosed
US-4101664-A FUNGICIDES, BACTERICIDES JANSSEN PHARMACEUTICA N.V. (BE) 1978-07-18 US disclosed
US-3936470-A FUNGICIDES, BACTERICIDES JANSSEN PHARMACEUTICA N.V. (BE) 1976-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795169-B2 MAP4K4 inhibitors MAP4K4, MAP4K2, MAP4K5 MAPT 315/4885MAPK1 31/4885KDM4E 742/4885
US-20240360082-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS PNPO, PDXK, PLPBP MAPT 2080/4885MAPK1 773/4885KDM4E 1906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.